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A B S T R A C T
Elevated levels of heat shock proteins (HSPs) contribute to tumor cell survival and mediate protection
against radiation-induced cell death. Hsp90 inhibitors are promising radiosensitizers but also activate
heat shock factor 1 (HSF1) and thereby induce the synthesis of cytoprotective Hsp70. In this study the
heat shock response inhibitor NZ28 either alone or in combination with the Hsp90 inhibitor NVP-
AUY922 was investigated for radiosensitizing effects, alterations in cell cycle distribution and effects on
migratory/invasive capacity of radioresistant tumor cells. NZ28 reduced the constitutive and NVP-
AUY922-induced Hsp70 expression by inhibition of the HSF1 activity and inhibited migration and invasion
in human lung and breast tumor cells. Treatment of tumor cells with NZ28 signiﬁcantly increased their
radiation response. One possible mechanism might be a decrease of the radioresistant S-phase. When
combined with the Hsp90 inhibitor NVP-AUY922 the concentration of NZ28 could be signiﬁcantly reduced
(1/10th–1/20th) to achieve the same radiosensitization. Our results demonstrate that a dual targeting
of Hsp70 and Hsp90 with NZ28 and NVP-AUY922 potentiates the radiation response of tumor cells that
are otherwise resistant to ionizing radiation.
© 2015 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY-
NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Introduction
The major stress-inducible molecular chaperone, heat shock
protein 70 (Hsp70, Hsp70A1A), fulﬁlls a variety of housekeeping and
cytoprotective functions. Normal cells constitutively express low
amounts of Hsp70. Following a broad variety of different stress
stimuli (e.g. heat shock, Hsp90 inhibition) the expression of Hsp70
is strongly increased. The main factor which is involved in the tran-
scription of Hsp70 is heat shock factor 1 (HSF1). After trimerization
HSF1 translocates to the nucleus and binds to the heat shock element
(HSE) in the promoter region of Hsp70. HSF1 activation is regu-
lated by posttranslational modiﬁcations such as phosphorylation,
sumoylation and deacetylation [1].
In contrast to normal cells, HSF1 and Hsp70 are highly
overexpressed in tumor cells already under physiological conditions
and thus contribute to tumor cell survival, migration, invasion
and angiogenesis [1–6]. High HSF1 and Hsp70 levels are associ-
ated with poor prognosis, metastasis and therapy resistance [1,7,8].
Consequently, a knock-down of HSF1 or Hsp70 results in an in-
creased radiation-induced cell killing [9–12]. The small molecular
weight inhibitor NZ28 was found to reduce HSF1 and Hsp70 levels
and therefore is meant to exert effects similar to a HSF1 depletion
[13,14].
Apart from HSF1/Hsp70, Hsp90 is an attractive anticancer target
since Hsp90 chaperones a number of oncogenic client proteins
(e.g. HER2, mutant EGFR, AKT, BCR-ABL, survivin, mutant p53, HIF-1α,
MMP2, hTERT). Several Hsp90 inhibitors are currently tested in clin-
ical trials. By a simultaneous degradation of multiple oncogenic client
proteins, Hsp90 inhibitors reduce tumor cell proliferation and
enhance the radiosensitivity of tumor cells [15,16]. However, a neg-
ative side effect of Hsp90 inhibition is the activation of HSF1 and
subsequently the induction of Hsp70. Therefore, a down-regulation
or inhibition of HSF1 or Hsp70 increases the sensitivity of tumor
cells toward Hsp90 inhibitors [14,17–20]. Herein, we studied the
role of the heat shock response inhibitor NZ28 either alone or in
combination with the Hsp90 inhibitor NVP-AUY922 on the
activation of HSF1, Hsp70 expression, migration, invasion and ra-
diosensitivity of radioresistant human tumor cell lines.
Abbreviations: Hsp, heat shock protein; HSF1, heat shock factor 1; HSE, heat shock
element; SER, sensitizing enhancement ratio.
* Corresponding author. Department of Radiation Oncology, Technische Universität
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Fig. 1. NZ28 reduces HSF1 activity and Hsp70 expression in tumor cells. (A) Representative immunoblot showing the constitutive expression of Hsp70 in EPLC-272H, H1339,
T47D and MDA-MB-231 tumor cells and human fetal lung ﬁbroblasts (HFL). (B) Representative HSF1 phospho S326 (pHSF1) and Hsp70 immunoblots of EPLC-272H, H1339,
T47D and MDA-MB-231 tumor cells that were treated for 24 h with different concentrations of NZ28. DMSO (0.2%) treated cells served as control (0 μM NZ28). The protein
bands were quantiﬁed by densitometry using ImageJ. Numbers under the lanes represent the expression levels of pHSF1 or Hsp70 relative to β-actin. The value of control
cells was set to 1 for each cell line. (C) Luciferase assay of EPLC-272H, H1339, T47D and MDA-MB-231 tumor cells transfected with a HSF1 responsive ﬁreﬂy luciferase con-
struct and treated with 10 or 20 μM NZ28 for 24 h. The luciferase activity of vehicle (0.2% DMSO) treated cells (0 μM NZ28) was set to 1. Data are expressed as mean ± SEM
of at least 3 independent experiments (**p ≤ 0.01, **p ≤ 0.01, ***p ≤ 0.001). (D) The Hsp70 mRNA expression in H1339 and T47D cells treated with 20 μM NZ28 or 0.2% DMSO
(0 μM NZ28) for 24 h was quantiﬁed by qRT-PCR. The mRNA levels were normalized to the housekeeping gene β-actin. Data are expressed as mean ± SEM of 3 independent
experiments (***p ≤ 0.01).
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Fig. 2. NZ28 inhibits migration and invasion. (A) Migratory capacity was assessed by a wound healing assay. EPLC-272H, H1339, T47D and MDA-MB-231 tumor cells were
plated in culture-inserts and 24 h later, inserts were removed and cells were treated with 2, 10 and 20 μM NZ28 (0 h). 0.2% DMSO diluted in PBS was used as control (0 μM
NZ28). The percentage of wound closure was quantiﬁed at the indicated time points. Data are expressed as mean ± SEM of 3 independent experiments (*p ≤ 0.05, **p ≤ 0.01,
***p ≤ 0.001). (B) The invasive capacity of EPLC-272H, H1339, T47D and MDA-MB-231 tumor cells treated with 2 and 20 μM NZ28 for 24 h in relation to vehicle (0.2% DMSO)
treated cells was determined by a transwell Matrigel invasion assay. Data are expressed as mean ± SEM of 4 independent experiments (*p ≤ 0.05, **p ≤ 0.01***, p ≤ 0.001).
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Materials and methods
Reagents and treatment
10 mM stock solutions of NZ28 (M. Sherman; Boston University School of Med-
icine, USA) and NVP-AUY922 (Novartis) were prepared in 100% DMSO. Dilutions were
performed in PBS. A vehicle control with the respective amount of DMSO diluted
in PBS (maximal 0.2%) was used in all experiments. If not indicated otherwise, cells
were incubated for 24 h with NZ28 and/or NVP-AUY922.
Cells and cell culture
The human lung (H1339 and EPLC-272H) and breast (MDA-MB-231 and T47D)
cancer cell lines and human fetal lung ﬁbroblasts (HFL) (kindly provided by Prof.
Rodemann) were cultured as described previously [15,21,22]. The authenticity of the
tumor cell lines was tested by the DSMZ (German Collection of Microorganisms and
Cell Cultures). Cells were routinely checked and determined as negative for myco-
plasma contamination.
Western blot analysis
Cells were lysed as described previously [23]. On immunoblots, proteins were
detected with antibodies against Hsp70 (ADI-SPA-810, Enzo Life Sciences), HSF1
phospho S326 (pHSF1) (ab76076, abcam) and β-actin (A5316, Sigma-Aldrich). The
protein bands were quantiﬁed by densitometry using ImageJ. The expression levels
of pHSF1 or Hsp70 were calculated relative to β-actin.
HSE luciferase assay
In order to determine the HSF1 activity, cells were transfected with a HSE re-
porter plasmid that contains a HSF1 responsive ﬁreﬂy luciferase construct (Qiagen).
On day one after transfection, cells were treated with NZ28 for 24 h. The luciferase
activity was measured using the Dual Glo Luciferase assay system (Promega). A con-
stitutive Renilla luciferase construct served as an internal control.
Quantitative real-time PCR
To investigate the mRNA expression of Hsp70, RNA was isolated with the RNeasy
Mini Kit (Qiagen) and reverse transcription of RNAwas performedwith the QuantiTect
Reverse Transcription Kit (Qiagen) according to the manufacturer’s instructions. qRT-
PCR was performed in a LightCycler 480 (Roche) by using the QuantiTect SYBR Green
PCR Kit (Qiagen). Primers used for qRT-PCR were as follows: ACTB-F:
GACGACATGGAGAAAATCTG, ACTB-R: ATGATCTGGGTCATCTTCTC, HspA1A-F:
AATTTCCTGTGTTTGCAATG, HspA1A-R: AAAATGGCCTGAGTTAAGTG. Each sample was
measured in triplicate and the mean Ct was calculated. Relative expression was cal-
culated using the ΔΔCt method. The mRNA expression of β-actin was used as an
internal control.
Wound healing assay
To determine the migratory capacity of tumor cells, wound healing assays were
performed. Cells were plated in culture-inserts (Ibidi) and 24 h later, inserts were
removed and cells treated with 2, 10 and 20 μM NZ28 (0 h). 0.2% DMSO diluted in
PBS was used as control (0 μM NZ28). After 24 h the medium was replaced by fresh
medium without NZ28 or DMSO. The migration of cells into the cell-free gap was
monitored microscopically and quantiﬁed using ImageJ’s wound healing tool.
Matrigel invasion assay
Invasion of tumor cells was measured by transwell Matrigel assay. Cells were
seeded in 6 cm dishes and 24 h later treated with 2 and 20 μM NZ28. 0.2% DMSO
diluted in PBS was used as control (0 μM NZ28). After 24 h, cells were trypsinized,
counted and plated in Biocoat™Matrigel® Invasion chambers (Corning) in serum-
free medium. 10% FCS-containing medium was added as a chemo-attractant to the
wells in the bottom. Transmigrated cells were ﬁxed after 24 h, stained with DAPI
and counted. The number of NZ28-treated cells that migrated through the matrigel
was calculated in relation to vehicle treated (0.2% DMSO) cells (0 μM NZ28).
Clonogenic assay and irradiation
To measure the radiosensitivity, clonogenic assays were performed as de-
scribed previously [15]. The cells were seeded in 12-well plates, one day later treated
with NZ28/NVP-AUY922 and 24 h later irradiated using the RS225A irradiation device
(GulmayMedical Ltd) at a dose rate of 1 Gy/min (70 keV). After irradiation themedium
was exchanged by a drug-free medium. On day 9 (H1339) or 16 (T47D) after seeding,
colonies were ﬁxed, stained and counted. Survival curves were ﬁtted to the linear
quadratic model using Sigmaplot (Systat Software Inc).
Fig. 3. NZ28 increases radiosensitivity of tumor cells. Clonogenic survival of cells
treated with NZ28 (A) or with NZ28 and irradiation (B). (A) One day after seeding
H1339 and T47D cells were treated with different concentrations of NZ28. DMSO
(0.2%) treated cells served as control. After 24 h the mediumwas replaced by a drug-
free medium. Colonies were ﬁxed either 9 (H1339) or 16 (T47D) days after seeding.
The survival fractions were calculated relative to the DMSO-treated control. IC50 (half
maximal inhibitory concentration) values are indicated. (B) One day after seeding
H1339 and T47D cells were treated with NZ28 for 24 h, then irradiated and imme-
diately after irradiation fresh mediumwithout NZ28 was added. DMSO treated cells
served as control (0 μM NZ28). Colonies were ﬁxed either 9 (H1339) or 16 (T47D)
days after seeding. The survival fractions were calculated after normalization for cell
killing by NZ28 alone. Data are expressed as mean ± SEM of at least 3 independent
experiments (*p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001).
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Cell cycle analysis
To analyze the cell cycle distribution, cells were ﬁxed, stained with propidium
iodide in the presence of RNase and analyzed on a FACSCalibur ﬂow cytometer (BD
Biosciences) as described previously [24]. The cell cycle distribution was calcu-
lated using Modﬁt software (Verity Software House Inc).
Statistics
Statistical analysis was performed using SPSS 18.0.2 software (IBM). The St-
udent’s t-test was used to evaluate signiﬁcant differences (*p ≤ 0.05, **p ≤ 0.01,
***p ≤ 0.001). All experiments were independently performed at least 3 times.
Results
NZ28 decreases Hsp70 levels and inhibits activation of HSF1
As shown in Fig. 1A, lung (EPLC-272H, H1339) and breast (T47D,
MDA-MB-231) cancer cell lines exhibited high constitutive Hsp70
levels in comparison to normal human fetal lung ﬁbroblasts (HFL).
Knock-down of HSF1 revealed that the high constitutive Hsp70 ex-
pression levels in H1339 tumor cells depend on HSF1 [25].
Following treatment with different concentrations of the small
molecule inhibitor NZ28 [13,14] the Hsp70 levels decreased in all
4 cancer cell lines (Fig. 1B). In parallel, the amount of HSF1 phos-
phorylated at serine 326 (pHSF1 Ser326) was down-regulated, which
indicates that the HSF1 activation was reduced by NZ28 (Fig. 1B)
[26]. The inhibitory effect of 10 and 20 μM NZ28 on the HSF1 ac-
tivity was conﬁrmed in EPLC-272H, H1339, T47D and MDA-MB-
231 tumor cells transfected with a HSE reporter luciferase gene
(Fig. 1C). Quantitative RT-PCR was performed to address the ques-
tion of whether inhibition of HSF1 by NZ28 affects the transcription
of Hsp70. In line with the reduced HSF1 activity, NZ28 signiﬁ-
cantly down-regulated Hsp70mRNA expression in H1339 and T47D
tumor cells (Fig. 1D). These data suggest that NZ28 inhibits the basal
HSF1 activity and down-regulates constitutive Hsp70 transcrip-
tion in tumor cells.
NZ28 inhibits tumor cell migration and invasion
Hsp70 and HSF1 were found to be associated with the migra-
tory capacity of tumor cells [2,4,6,11]. Therefore, we examined
whether NZ28 affects tumor cell migration. In wound healing assays
we could show that NZ28 signiﬁcantly inhibited the migration of
lung and breast cancer cell lines in a concentration-dependent
manner (Fig. 2A, Supplementary Fig. S1). In addition to migration,
the invasive capacity through Matrigel was also signiﬁcantly in-
hibited by NZ28 in all 4 cell lines (Fig. 2B).
NZ28 increases the radiosensitivity
A comparison of the intrinsic radiosensitivity of the 4 different
tumor cell lines revealed that H1339 and T47D cells are the twomost
radioresistant tumor cell lines (indicated by the highest D50 values)
(D50: EPLC-272H, 3.7 Gy; H1339, 4.0 Gy; T47D, 4.5 Gy; MDA-MB-
231, 3.2 Gy). Therefore, H1339 and T47D cells were chosen to test
the radiosensitizing effect of NZ28. NZ28 alone similarly affected
the clonogenic survival of T47D and H1339 cells with IC50 (half
maximal inhibitory concentration) values of 14.3 and 17.1 μM, re-
spectively (Fig. 3A). When combinedwith irradiation, concentrations
above 5 μM NZ28 signiﬁcantly reduced the survival fraction of both
cell lines (Fig. 3B, Table 1). The radiosensitizing effect of NZ28 was
conﬁrmed by calculating the sensitizing enhancement ratios (SER)
which were 1.99 in H1339 and 1.34 in T47D cells treated with 20 μM
NZ28 (Table 1).
For a better understanding of the mechanisms that result in the
NZ28-mediated radiosensitization, apoptosis, DNA double strand
breaks and cell cycle distribution were analyzed. Neither radiation-
induced apoptosis (Caspase-3, 24 h post irradiation) nor the amount
of residual DNA double strand breaks (γH2AX/p53BP1 foci, 24 h post
irradiation) were signiﬁcantly affected by a treatment with 20 μM
NZ28 (data not shown). In contrast, NZ28 signiﬁcantly reduced the
fraction of tumor cells in the radioresistant S-phase from 33.8% to
25.5% in H1339 and from 10.5% to 4.0% in T47D cells (Fig. 4).
A combined treatment with low doses of NZ28 and NVP-AUY922
potentiates the radiosensitivity of tumor cells
We have previously shown that a continuous treatment of H1339
cells with the Hsp90 inhibitor NVP-AUY922 can enhance the ra-
diosensitivity but also increases the expression of Hsp70 [15]. Herein,
we investigated whether NZ28 can inhibit the NVP-AUY922-
induced activation of HSF1 and the expression of Hsp70 to increase
the NVP-AUY922-mediated radiosensitization. As shown in Fig. 5,
NZ28 reduced the NVP-AUY922-induced activation of HSF1 (as de-
termined by a phosphorylation of serine 326) and the expression
of Hsp70. As a consequence, a combined treatment of tumor cells
with low concentrations of NZ28 (1 μM) and NVP-AUY922 (2 nM)
Table 1
Summary of radiobiological parameters depicted in Figs. 3B and 6.
SF2a SF4a SF6a α [Gy−1]b β [Gy−2]b D50 [Gy]c SERd
H1339
Control 0.79 ± 0.03 0.47 ± 0.02 0.29 ± 0.03 0.085 0.022 4.01 1.00
1 μM NZ28 0.82 ± 0.03 0.40 ± 0.05 0.24 ± 0.04 0.049 0.037 3.74 1.07
5 μM NZ28 0.69 ± 0.04 0.33 ± 0.04** 0.18 ± 0.04 0.103 0.026 3.18 1.18
10 μM NZ28 0.60 ± 0.02*** 0.36 ± 0.02* 0.17 ± 0.02 0.179 0.013 2.73 1.47
20 μM NZ28 0.50 ± 0.06*** 0.24 ± 0.05*** 0.10 ± 0.03* 0.225 0.010 2.01 1.99
2 nM NVP-AUY922 0.75 ± 0.06 0.42 ± 0.02 0.22 ± 0.03 0.101 0.026 3.56 1.12
1 μM NZ28 + 2 nM NVP-AUY922 0.64 ± 0.04* 0.32 ± 0.02** 0.17 ± 0.04 0.191 0.019 2.83 1.41
T47D
Control 0.86 ± 0.06 0.53 ± 0.03 0.33 ± 0.01 0.035 0.027 4.46 1.00
1 μM NZ28 0.83 ± 0.04 0.48 ± 0.04 0.24 ± 0.04 0.024 0.037 4.00 1.12
5 μM NZ28 0.91 ± 0.06 0.43 ± 0.02* 0.22 ± 0.06 −0.057 0.060 3.92 1.14
10 μM NZ28 0.92 ± 0.22 0.53 ± 0.05 0.21 ± 0.02** −0.067 0.055 4.19 1.06
20 μM NZ28 0.74 ± 0.11 0.38 ± 0.02* 0.17 ± 0.05* 0.083 0.037 3.34 1.34
2 nM NVP-AUY922 0.81 ± 0.06 0.44 ± 0.02* 0.15 ± 0.02* −0.001 0.052 3.64 1.22
1 μM NZ28 + 2 nM NVP-AUY922 0.78 ± 0.03 0.28 ± 0.01*** 0.11 ± 0.01*** −0.033 0.082 3.12 1.43
a SF2, SF4, SF6, survival fraction at 2, 4 and 6 Gy, respectively. Mean values ± SEM are shown. Signiﬁcant differences between vehicle control and cells treated with NZ28
and/or NVP-AUY922 are indicated (*p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001).
b α and β values were derived from the linear quadratic equation SF = exp [−α × D −β × D2].
c D50, dose [Gy] to reduce survival fraction to 50%.
d SER, sensitizing enhancement ratio = D50 (irradiation)/D50 (irradiation and drug). A SER greater than 1.20 is indicative for radiosensitization (indicated in bold).
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Fig. 4. NZ28 reduces the fraction of tumor cells in the radioresistant S-phase. The cell cycle distribution was determined after a 24 h treatment with 20 μM NZ28. DMSO
(0.02%) treated cells served as control (0 μM NZ28). Representative histograms (A) and mean ± SEM (B) of 3 (H1339) and 5 (T47D) independent experiments are shown
(*p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001).
Fig. 5. NZ28 reduces NVP-AUY922-induced pHSF1 and Hsp70 levels. Representative HSF1 phospho S326 (pHSF1) and Hsp70 immunoblots. H1339 and T47D tumor cells
were treated with 0, 2, 5, 10 and 20 μM NZ28 and 100 nM NVP-AUY922 (NVP) for 24 h. DMSO (0.2%) treated cells served as control (ctrl). A gap was included between
control and treated samples because the lanes were not adjacent but samples were loaded on the same gel and the blot was exposed for the same period of time. The protein
bands were quantiﬁed by densitometry using ImageJ. Numbers under the lanes represent the expression of pHSF1 or Hsp70 relative to β-actin. The value of control cells
was set to 1 for each cell line.
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signiﬁcantly enhanced the radiosensitivity with SER values of 1.41
and 1.43 for H1339 and T47D cells, respectively (Fig. 6 and Table 1).
The radiosensitization which was achieved by a combined treat-
ment with low concentrations of NZ28 and NVP-AUY922 was
comparable to that of a single treatment with NZ28 at 10–20-fold
higher concentrations (Fig. 3B, Table 1).
Discussion
Hsp70 is abundantly overexpressed in a variety of human tumor
cells and high Hsp70 levels are associated with poor clinical outcome
since Hsp70 promotes tumor cell survival and contributes to ra-
dioresistance [10,12]. The group of M. Sherman demonstrated that
the small molecule inhibitor NZ28 reduces both the stress-induced
and basal Hsp70 expression levels in HER2-positive cancer cell lines
[13,14]. In line with their data we show that NZ28 down-regulated
basal and NVP-AUY922-induced Hsp70 expression in different lung
and breast cancer cell lines. Moreover, we could show that NZ28
reduces the phosphorylation of HSF1 at serine 326 and thus inhib-
its HSF1 transcriptional activity as measured by a luciferase reporter
assay. Concomitantly the Hsp70 mRNA levels were found to be
reduced under non-stressed conditions. This suggests that NZ28
down-regulates Hsp70 expression via inhibition of HSF1. Zaarur et al.
showed that NZ28 does not alter heat-induced Hsp70 mRNA levels
and aweak inhibition of the HSF1 transcriptional activity [14]. There-
fore, they propose a post-transcriptional reduction of the stress-
induced Hsp70 expression by NZ28. This discrepancy might be
explained by the fact that the HSF1 activation and Hsp70 expres-
sion is regulated differently by NZ28 under stressed and non-
stressed conditions or by the use of different tumor cell lines,
incubation times and NZ28 concentrations.
Previous studies demonstrated that knocking-down Hsp70 or
HSF1 reduces the invasiveness of tumor cells [3,4,11]. Consistent
with these ﬁndings, we could show that NZ28 decreases migra-
tion and invasion of different human tumor cell lines. Silencing HSF1
or Hsp70 by siRNA is assumed to increase the radiosensitivity of
human tumor cell lines [9–12]. However, only few inhibitors tar-
geting HSF1 and/or Hsp70 have been tested with respect to their
radiosensitizing capacity and the published data have been con-
troversially discussed. As an example, the small molecule Hsp70
inhibitor VER-155008 has been shown to increase the radiosensi-
tivity of A549 lung cancer cells [27], whereas the HSF1 inhibitor
KNK437 exerted an opposite effect in glioblastoma cells [28]. We
could demonstrate that NZ28 increases the radiation response of
different human lung and breast cancer cells. One possible mech-
anismmight be a decrease of the radioresistant S-phase. In line with
our data, the Hsp70 inhibitors, VER-155008 and piﬁthrin-μ have been
found to exert identical effects on the cell cycle distribution
[27,29,30].
Hsp90 inhibition is a promising strategy in cancer therapy.
However, clinically applied Hsp90 inhibitors induce the synthesis
of the cytoprotective chaperone Hsp70 by activation of HSF1. There-
fore, it was not astonishing to ﬁnd that inhibition of HSF1 and/or
Hsp70 can sensitize tumor cells toward Hsp90 inhibitors
[14,17–19,31–34]. In contrast, knowledge on the effects of HSF1/
Hsp70 and Hsp90 inhibition on radiation therapy is limited [35].
Here, we could show that a combined treatment of tumor cells with
low, non-toxic concentrations of NZ28 and NVP-AUY922 potenti-
ates the radiosensitization of different tumor cells.
We have demonstrated that NZ28 reduces HSF1 activation
and expression of cytoprotective Hsp70, inhibits migration and
invasion, decreases the percentage of tumor cells in the radiore-
sistant S-phase and increases their radiosensitivity. In combination
with NVP-AUY922, 1/10th–1/20th of the concentration of NZ28
was suﬃcient to achieve a signiﬁcant radiosensitization com-
pared to the treatment with a single drug. Therefore, we assume
that a simultaneous inhibition of Hsp90 and HSF1/Hsp70 com-
bined with radiotherapy might provide a promising anti-cancer
strategy.
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Fig. 6. Treatment with low concentrations of NZ28 and NVP-AUY922 potentiates
radiosensitivity of tumor cells. One day after seeding H1339 and T47D cells were
treated with 1 μM NZ28 and 2 nM NVP-AUY922 (NVP). 24 h after treatment cells
were irradiated and immediately after irradiation fresh medium without NZ28/
NVP-AUY922 was added. DMSO (0.01%) treated cells served as control. Colonies were
ﬁxed either 9 (H1339) or 16 (T47D) days after seeding. The survival fractions were
calculated after normalization for cell kill by NZ28 and/or NVP-AUY922. Data are
expressed as mean ± SEM of at least 3 independent experiments (*p ≤ 0.05, **p ≤ 0.01,
***p ≤ 0.001).
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